Joel M Gelfand Highlights Platelet RNA Signature in Psoriasis
Joel M Gelfand, Director Center for Clinical Sciences in Dermatology at University of Pennsylvania School of Medicine, shared a post on LinkedIn:
“An under investigated topic in psoriasis is its impact on platelets. Here, Michael Garshick demonstrates that even when psoriasis is well controlled with biologics platelets remain activated and have a newly discovered RNA signature that predicts future cardiovascular events.
Details here
Álvaro González Cantero has also recently demonstrated that patients with well controlled psoriasis have residual systemic inflammation
Details here
These findings provide more evidence that simply treating the skin may not be enough to lower CV risk and that more holistic multi-pronged approaches are needed. Note, I am a collaborator and author on both papers”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch